WallStSmart

Aurora Cannabis Inc (ACB)vsTakeda Pharmaceutical Co Ltd ADR (TAK)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Takeda Pharmaceutical Co Ltd ADR generates 1470566% more annual revenue ($4.62T vs $314.07M). TAK leads profitability with a -3.5% profit margin vs -38.3%. TAK earns a higher WallStSmart Score of 53/100 (C-).

ACB

Avoid

29

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 3/9Altman Z: -10.67

TAK

Buy

53

out of 100

Grade: C-

Growth: 4.7Profit: 4.5Value: 6.7Quality: 5.0
Piotroski: 4/9Altman Z: 1.20

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ACB2 strengths · Avg: 10.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0410/10

Conservative balance sheet, low leverage

TAK4 strengths · Avg: 9.8/10
PEG RatioValuation
0.4010/10

Growing faster than its price suggests

Price/BookValuation
1.4x10/10

Reasonable price relative to book value

Free Cash FlowQuality
$212.65B10/10

Generating 212.6B in free cash flow

Market CapQuality
$64.66B9/10

Large-cap with strong market position

Areas to Watch

ACB4 concerns · Avg: 2.5/10
Market CapQuality
$257.04M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-7.9%2/10

ROE of -7.9% — below average capital efficiency

Revenue GrowthGrowth
-8.8%2/10

Revenue declined 8.8%

TAK4 concerns · Avg: 2.0/10
Return on EquityProfitability
5.2%3/10

ROE of 5.2% — below average capital efficiency

EPS GrowthGrowth
-9.8%2/10

Earnings declined 9.8%

Altman Z-ScoreHealth
1.202/10

Distress zone — elevated risk

Profit MarginProfitability
-3.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : ACB

The strongest argument for ACB centers on Price/Book, Debt/Equity.

Bull Case : TAK

The strongest argument for TAK centers on PEG Ratio, Price/Book, Free Cash Flow. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.40 suggests the stock is reasonably priced for its growth.

Bear Case : ACB

The primary concerns for ACB are Market Cap, Piotroski F-Score, Return on Equity.

Bear Case : TAK

The primary concerns for TAK are Return on Equity, EPS Growth, Altman Z-Score.

Key Dynamics to Monitor

ACB carries more volatility with a beta of 1.42 — expect wider price swings.

TAK is growing revenue faster at 10.2% — sustainability is the question.

TAK generates stronger free cash flow (212.6B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

TAK scores higher overall (53/100 vs 29/100) and 10.2% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Aurora Cannabis Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Aurora Cannabis Inc. produces and distributes medical cannabis products globally. The company is headquartered in Edmonton, Canada.

Takeda Pharmaceutical Co Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.

Want to dig deeper into these stocks?